Longitudinal Microperimetric Changes of Macular Sensitivity in Stargardt Disease After 12 Months: ProgStar Report No. 13.
暂无分享,去创建一个
B. Munoz | E. Zrenner | S. Sadda | S. West | Y. Wolfson | J. Sunness | D. Birch | E. Schönbach | H. Scholl | M. Ip | R. Strauss | M. Ibrahim
[1] A. Cideciyan,et al. Faster Sensitivity Loss around Dense Scotomas than for Overall Macular Sensitivity in Stargardt Disease: ProgStar Report No. 14. , 2020, American journal of ophthalmology.
[2] J. Sahel,et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period: ProgStar Report No. 11. , 2019, JAMA ophthalmology.
[3] B. Munoz,et al. Longitudinal Changes of Fixation Location and Stability Within 12 Months in Stargardt Disease: ProgStar Report No. 12. , 2018, American journal of ophthalmology.
[4] A. Cideciyan,et al. Visual Acuity Change Over 24 Months and Its Association With Foveal Phenotype and Genotype in Individuals With Stargardt Disease: ProgStar Study Report No. 10 , 2018, JAMA ophthalmology.
[5] J. Sahel,et al. Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease (SMART) Study: Design and Baseline Characteristics (Report No. 1) , 2018, Ophthalmic Research.
[6] J. Sahel,et al. Detailed genetic characteristics of an international large cohort of patients with Stargardt disease: ProgStar study report 8 , 2018, British Journal of Ophthalmology.
[7] A. Cideciyan,et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9) , 2017, JAMA ophthalmology.
[8] J. Sahel,et al. Visual Acuity Change over 12 Months in the Prospective Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: ProgStar Report Number 6. , 2017, Ophthalmology.
[9] A. Cideciyan,et al. Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7 , 2017, JAMA ophthalmology.
[10] A. Cideciyan,et al. Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 5 , 2017, JAMA ophthalmology.
[11] B. Munoz,et al. Progression of Stargardt disease as measured by spectral-domain optical coherence tomography (SD-OCT) in the ProgStar Study , 2017 .
[12] A. Cideciyan,et al. Progression of Visual Acuity and Fundus Autofluorescence in Recent-Onset Stargardt Disease: ProgStar Study Report #4. , 2016, Ophthalmology. Retina.
[13] A. Cideciyan,et al. Fixation Location and Stability Using the MP-1 Microperimeter in Stargardt Disease: ProgStar Report No. 3. , 2017, Ophthalmology. Retina.
[14] S. Vujosevic,et al. Long-term longitudinal modifications in mesopic microperimetry in early and intermediate age-related macular degeneration , 2017, Graefe's Archive for Clinical and Experimental Ophthalmology.
[15] B. Roska,et al. Emerging therapies for inherited retinal degeneration , 2016, Science Translational Medicine.
[16] E. Zrenner,et al. Cross-sectional evaluation of microperimetric fixation location and stability in Stargardt disease in the ProgStar study , 2016 .
[17] J. Sahel,et al. Visual Acuity Loss and Associated Risk Factors in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 2). , 2016, Ophthalmology.
[18] J. Sahel,et al. The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1. , 2016, Ophthalmology.
[19] P. Melillo,et al. Macular function and morphologic features in juvenile stargardt disease: longitudinal study. , 2014, Ophthalmology.
[20] J. Sahel,et al. Gene therapy arrives at the macula , 2014, The Lancet.
[21] R. Ritch,et al. Optic disc progression and rates of visual field change in treated glaucoma , 2013, Acta ophthalmologica.
[22] W. Feuer,et al. The Impact of Surgical Intraocular Pressure Reduction on Visual Function Using Various Criteria to Define Visual Field Progression , 2012, Journal of glaucoma.
[23] T. Aleman,et al. Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials. , 2012, Investigative ophthalmology & visual science.
[24] L. da Cruz,et al. NIDEK MP1 IS ABLE TO DETECT SUBTLE DECLINE IN FUNCTION IN INHERITED AND AGE-RELATED ATROPHIC MACULAR DISEASE WITH STABLE VISUAL ACUITY , 2011, Retina.
[25] F. Ferris,et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. , 2010, Investigative ophthalmology & visual science.
[26] G. Rubin,et al. Test-retest variability of microperimetry using the Nidek MP1 in patients with macular disease. , 2009, Investigative ophthalmology & visual science.
[27] Hendrik P N Scholl,et al. Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2. , 2009, Investigative ophthalmology & visual science.
[28] J. Sunness,et al. RETINAL FUNCTION AND LOSS OF AUTOFLUORESCENCE IN STARGARDT DISEASE , 2008, Retina.
[29] J. Sunness. What you see is not always what you get in atrophic macular disease. , 2008, Retinal cases & brief reports.
[30] P. Charbel Issa,et al. Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. , 2007, Investigative ophthalmology & visual science.